Palvella Therapeutics, Inc.
PVLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,528 | $5,118 | $4,074 | $2,543 |
| G&A Expenses | $3,649 | $4,132 | $3,797 | $1,823 |
| SG&A Expenses | $3,649 | $4,132 | $3,797 | $1,823 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,177 | $9,250 | $7,871 | $4,366 |
| Operating Income | -$10,177 | -$9,250 | -$7,871 | -$4,366 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1,168 | -$221 | -$314 | $415 |
| Pre-Tax Income | -$11,345 | -$9,471 | -$8,185 | -$3,951 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,345 | -$9,471 | -$8,185 | -$3,951 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -0.86 | -3.68 | -0.88 |
| % Growth | -19.8% | 76.6% | -318.2% | – |
| EPS Diluted | -1.03 | -0.86 | -3.68 | -0.88 |
| Weighted Avg Shares Out | 11,064 | 11,053 | 2,226 | 2,226 |
| Weighted Avg Shares Out Dil | 11,064 | 11,053 | 2,226 | 2,226 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $690 | $752 | $0 |
| Interest Expense | $1,510 | $1,354 | $1,215 | $1,304 |
| Depreciation & Amortization | $10,177 | $0 | $0 | $0 |
| EBITDA | $342 | -$8,117 | -$6,970 | -$4,366 |
| % Margin | – | – | – | – |